287 related articles for article (PubMed ID: 9041721)
21. [Resistance to activated protein C. The most common cause of familial thrombophilia].
Larsen TB; Ravn HB; Lassen JF; Lund ED; Brandslund I
Ugeskr Laeger; 1996 Nov; 158(46):6584-8. PubMed ID: 8966822
[TBL] [Abstract][Full Text] [Related]
22. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons.
Dahlbäck B
Thromb Haemost; 1995 May; 73(5):739-42. PubMed ID: 7482395
[No Abstract] [Full Text] [Related]
23. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.
Bertina RM; Reitsma PH; Rosendaal FR; Vandenbroucke JP
Thromb Haemost; 1995 Jul; 74(1):449-53. PubMed ID: 8578504
[TBL] [Abstract][Full Text] [Related]
24. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?
Koeleman BP; van Rumpt D; Hamulyák K; Reitsma PH; Bertina RM
Thromb Haemost; 1995 Aug; 74(2):580-3. PubMed ID: 8584987
[TBL] [Abstract][Full Text] [Related]
25. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
Tripodi A; Negri B; Bertina RM; Mannucci PM
Thromb Haemost; 1997 Mar; 77(3):436-9. PubMed ID: 9065989
[TBL] [Abstract][Full Text] [Related]
26. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
Zöller B; Svensson PJ; He X; Dahlbäck B
J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
[TBL] [Abstract][Full Text] [Related]
27. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Montes MA; Fox EA; Longtine JA; Dorfman DM
Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
[TBL] [Abstract][Full Text] [Related]
28. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Zöller B; Holm J; Svensson P; Dahlbäck B
Thromb Haemost; 1996 Feb; 75(2):270-4. PubMed ID: 8815575
[TBL] [Abstract][Full Text] [Related]
29. The factor V gene A4070G mutation and the risk of venous thrombosis.
Alhenc-Gelas M; Nicaud V; Gandrille S; van Dreden P; Amiral J; Aubry ML; Fiessinger JN; Emmerich J; Aiach M
Thromb Haemost; 1999 Feb; 81(2):193-7. PubMed ID: 10063990
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H
Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526
[TBL] [Abstract][Full Text] [Related]
31. Factor V gene mutation is a risk factor for cerebral venous thrombosis.
Martinelli I; Landi G; Merati G; Cella R; Tosetto A; Mannucci PM
Thromb Haemost; 1996 Mar; 75(3):393-4. PubMed ID: 8701395
[TBL] [Abstract][Full Text] [Related]
32. Resistance to activated protein C: a major cause of inherited thrombophilia.
Jensen R; Ens GE
Clin Lab Sci; 1997; 10(4):219-22. PubMed ID: 10169621
[TBL] [Abstract][Full Text] [Related]
33. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
34. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
Kabukcu S; Keskin N; Keskin A; Atalay E
Clin Appl Thromb Hemost; 2007 Apr; 13(2):166-71. PubMed ID: 17456626
[TBL] [Abstract][Full Text] [Related]
35. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
Tans G; Nicolaes GA; Rosing J
Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
[TBL] [Abstract][Full Text] [Related]
36. Resistance to activated protein C and a novel factor V gene mutation.
Voelkerding KV
Clin Lab Med; 1996 Mar; 16(1):169-86. PubMed ID: 8867589
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
De Lucia D; De Francesco F; Marotta R; Maisto G; Meo D; Sessa M; Misso M; Galante M; Russo T; Pignalosa O; Napolitano M; Papa ML; Niglio A; Di Micco P
Exp Oncol; 2005 Jun; 27(2):159-61. PubMed ID: 15995637
[TBL] [Abstract][Full Text] [Related]
38. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
39. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance.
Kirschbaum NE; Foster PA
Thromb Haemost; 1995 Sep; 74(3):874-8. PubMed ID: 8571314
[TBL] [Abstract][Full Text] [Related]
40. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Tosetto A; Missiaglia E; Gatto E; Rodeghiero F
Thromb Haemost; 1997 Aug; 78(2):859-63. PubMed ID: 9268185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
